---
title: "Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
date: "2025-02-08 08:25:44"
summary: "Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 26,897 shares of Evolus and an aggregate of 99,826..."
categories:
  - "morningstar"
lang:
  - "en"
translations:
  - "en"
tags:
  - "morningstar"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

**Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)**

[Evolus, Inc.](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.evolus.com%2F&esheet=54202029&newsitemid=20250207494454&lan=en-US&anchor=Evolus%2C+Inc.&index=1&md5=89d7b6c49f77e3324480dc61b2ddfdf5) (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 26,897 shares of Evolus and an aggregate of 99,826 restricted stock units (RSUs) of the company’s common stock to 34 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant and vesting commencement date of February 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $13.11 per share, the closing price of Evolus’ common stock the date of grant. The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to the option vesting on each annual anniversary of the vesting commencement date. The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as applicable, covering the grant, including requirements to remain continuously employed on each vesting date.

**About Evolus, Inc.**

Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse™, and the exclusive distributor in Europe of Estyme®, a line of unique injectable hyaluronic acid (HA) gels. These injectable HA gels are currently in the late stages of the regulatory approval process, with plans, upon approval, for a launch starting in 2025.

Visit us at [www.evolus.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.evolus.com%2F&esheet=54202029&newsitemid=20250207494454&lan=en-US&anchor=www.evolus.com&index=2&md5=10af668177a7ace6ed070696aaccbae8), and follow us on [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fevolusaesthetic&esheet=54202029&newsitemid=20250207494454&lan=en-US&anchor=LinkedIn&index=3&md5=28d525988d7b377536c7f9d5bfcd38ee), [X](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FEvolusAesthetic&esheet=54202029&newsitemid=20250207494454&lan=en-US&anchor=X&index=4&md5=deb1b3ed8b11ff58f9d521378be80c98), [Instagram](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fevolus%2F&esheet=54202029&newsitemid=20250207494454&lan=en-US&anchor=Instagram&index=5&md5=ae6f47d6bb3aba6f646e914473c14e67) or [Facebook](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fevolusaesthetic%2F&esheet=54202029&newsitemid=20250207494454&lan=en-US&anchor=Facebook&index=6&md5=608ae245c7f92453a1b4e6b26e718bdb).

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.
  
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
  
Estyme® is a trademark of Symatese Aesthetics S.A.S.

 ![](https://cts.businesswire.com/ct/CT?id=bwnews&sty=20250207494454r1&sid=mstr3&distro=nx&lang=en)

**Evolus Contacts:**  
Investors:
  
Nareg Sagherian
  
Vice President, Head of Global Investor Relations and Corporate Communications
  
Tel: 248-202-9267
  
Email: [ir@evolus.com](mailto:ir@evolus.com)

Media:
  
Email: [media@evolus.com](mailto:media@evolus.com)

View source version on businesswire.com: <https://www.businesswire.com/news/home/20250207494454/en/>

[morningstar](https://www.morningstar.com/news/business-wire/20250207494454/evolus-reports-inducement-grants-under-nasdaq-listing-rule-5635c4)
